| | | |

Treating Advanced Peritoneal Mesothelioma with Spray-On Oxaliplatin

ByAlex Strauss
advanced peritoneal mesothelioma surgeon

European doctors have tested a new spray-on cancer drug that could be another treatment option for people with advanced peritoneal mesothelioma.

The drug is oxaliplatin. It is sold under the brand name Eloxatin. It is normally given by injection into a vein. But that can cause serious side effects, including stomach pain.

A new study published in the European Journal of Surgical Oncology suggests there may be a more effective way to get the benefits of oxaliplatin. Researchers found that using it as a spray for advanced peritoneal mesothelioma extended survival with fewer side effects.

PIPAC for Advanced Peritoneal Mesothelioma

As Surviving Mesothelioma first reported last spring, pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new way to deliver cancer medicines.

During PIPAC, mesothelioma chemotherapy drugs are “sprayed” as gas directly onto the site of the cancer. This allows the application to be very precise. PIPAC is performed through a small incision using a laparoscope for guidance.

Potential advantages of PIPAC for advanced peritoneal mesothelioma patients are:

  • Less risk of pain and infection than an open procedure
  • May be repeated to maintain cancer control
  • Aerosol droplets may be absorbed into the tissue better than liquid medicine
  • More precise than systemic chemotherapy or even HIPEC so side effects are lessened
  • Usable in patients who are not candidates for surgery and heated intraperitoneal chemotherapy (HIPEC) treatment

These factors can make PIPAC a better option for delivering certain kinds of cancer drugs. Right now, PIPAC is still in clinical trials. But European doctors have already used it to treat thousands of patients with recurrent advanced peritoneal mesothelioma.

Delivering Oxaliplatin with PIPAC

Oxaliplatin is a platinum-based drug that is most often used to treat colorectal cancer. It is believed to work by making it impossible for cancer cells to duplicate their DNA.

In the newest PIPAC study, a team of French and Swiss doctors gave oxaliplatin to people with several kinds of peritoneal cancer including advanced peritoneal mesothelioma.

If they are not candidates for surgery, peritoneal mesothelioma patients have few good treatment options. The goal of the new study was to see if PIPAC would make oxaliplatin treatment easier for mesothelioma patients and others to tolerate.

Promising Results for Advanced Peritoneal Mesothelioma Patients

More than 100 patients with unresectable peritoneal cancer received the PIPAC-Ox treatment. Twenty-three patients reported abdominal pain, but only 9 had pain so bad that they had to change drugs.

Patients had an average of 2.5 procedures each. About a third of them saw improvements in their cancer symptoms.

The researchers conclude that PIPAC-Ox “appears to be a safe treatment that offers good symptom control and promising survival” for patients with advanced peritoneal mesothelioma and other peritoneal cancers.

Source:

Sgarbura, O, et al, “Oxaliplatin use in pressurized intraperitoneal aerosol chemotherapy (PIPAC) is safe and effective: A multicenter study”, May 9, 2019, European Journal of Surgical Oncology, Epub ahead of print, https://www.ejso.com/article/S0748-7983(19)30445-7/fulltext

Giger-Pabst, U, et al, “Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) for the treatment of malignant mesothelioma”, April 18, 2018, BMC Cancer, https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4363-0

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    Does Radiotherapy Reduce Mesothelioma Pain?

    ByAlex Strauss

    A new study says there is not enough evidence to support the use of radiotherapy for the treatment of pain associated with malignant pleural mesothelioma. Researchers at the University of Edinburgh in Scotland reviewed a range of past studies on mesothelioma pain and radiotherapy by searching databases that date back as far as 1974. To be eligible to be included in their review, the study had to focus on malignant pleural mesothelioma and radiotherapy given “with the intent of improving pain”. The study also had to report doses and fractionation of the radiotherapy and how the pain responded. In all, the researchers found eight studies on mesothelioma pain and radiotherapy that met the criteria. Two of the studies were prospective…

  • |

    Ape Virus Shrinks Mesothelioma Tumors in Lab

    ByAlex Strauss

    A virus that causes leukemia in gibbon apes may have the power to help fight malignant mesothelioma in people. Gibbon ape leukemia virus (GALV) has been tested for years as a viral vector, a carrier of therapeutic genetic information, in the treatment of various human illnesses, including cancer. A new study in Japan compared GALV with a leukemia virus derived from mice to see which carrier communicated most efficiently with mesothelioma cells. While both types of viruses replicated in most of the mesothelioma cell lines tested, the mouse-derived virus was not effective in a mesothelioma cell line called ACC-MESO-1. In this cell line, only the GALV spread efficiently both in culture and in mice that had been given human mesothelioma…

  • | |

    Radiotherapy for Mesothelioma: Better But Still Limited

    ByAlex Strauss

    A form of highly-targeted radiation therapy for mesothelioma is better than it used to be, but is still risky. That is the message of a recent article on intensity-modulated radiation therapy (IMRT) in Seminars in Thoracic and Cardiovascular Surgery. Author Kenneth E. Rosenzweig, MD, a Radiation Oncologist with Mount Sinai Hospital in New York, reviewed recent studies on IMRT and mesothelioma. He concludes that, while the “troubling toxicity” associated with IMRT when it was first introduced has not been entirely eliminated, the fact that clinicians now have more experience with it is making a positive difference for mesothelioma patients. Before targeted therapies like IMRT were available, high-dose radiation was not usually a feasible option for mesothelioma since the irregular shape…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Repeat HIPEC Improves Mesothelioma Survival

    ByAlex Strauss

    If one cytoreductive surgery and HIPEC procedure for mesothelioma is good, subsequent treatments may be even better. That is the central message of research conducted at the Moffitt Cancer Center in Florida. The study’s aim was to assess overall survival among peritoneal mesothelioma patients who had not just one, but two or more rounds of heated intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The cytoreduction/HIPEC approach has become popular for peritoneal mesothelioma, a treatment-resistant cancer of abdominal membranes caused by asbestos. Cytoreductive surgery involves removing as much of the mesothelioma tumor as possible from the abdomen. Because the shape and spreading pattern of mesothelioma tumors make complete cytoreduction difficult, the surgery is often followed by a rinse with a heated solution…